You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
|
|---|---|
| Published in |
Frontiers in endocrinology, November 2015
|
| DOI | 10.3389/fendo.2015.00168 |
| Pubmed ID | |
| Authors |
Jun Zhang, Yang Li |
| Abstract |
Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabolic parameters. Many different approaches have been pursued targeting FGF21 and its receptors to develop therapeutics for treating type 2 diabetes and other aspects of metabolic conditions. In this article, we summarize some of these key approaches and highlight the potential challenges in the development of these agents. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Spain | 1 | 1% |
| Unknown | 69 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 17% |
| Student > Master | 12 | 17% |
| Student > Bachelor | 12 | 17% |
| Researcher | 9 | 13% |
| Student > Doctoral Student | 4 | 6% |
| Other | 10 | 14% |
| Unknown | 12 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 25% |
| Agricultural and Biological Sciences | 14 | 20% |
| Biochemistry, Genetics and Molecular Biology | 10 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Veterinary Science and Veterinary Medicine | 2 | 3% |
| Other | 8 | 11% |
| Unknown | 16 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2018.
All research outputs
#7,204,882
of 25,373,627 outputs
Outputs from Frontiers in endocrinology
#2,019
of 13,012 outputs
Outputs of similar age
#84,529
of 296,930 outputs
Outputs of similar age from Frontiers in endocrinology
#12
of 42 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 13,012 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,930 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.